After conducting a vaccination trial in Assam, Andhra Pradesh, Punjab and Gujarat on December 28 and 29, the center has planned to extend the drill to the rest of the country so that once a vaccine injection is approved for emergency use , the vaccine is administered. continues smoothly anywhere. All state capitals will conduct drills at at least three session sites on January 2. Some states will also include districts that are located in difficult terrain or have poor logistical support.
In vaccine testing, the entire process of transporting vaccines from storage to site, administering them to candidates, data feed into the Co-WIN app is practiced without any actual vaccine. For example, in the Gujarat trial, 475 beneficiaries underwent the fictitious procedure, the main objective of which is to identify if there are any gaps in the planned process. Managing crowds at a booth while maintaining social distancing guidelines within the booth is also practiced in drills.
Also read: India will likely start the new year with a Covid vaccine, hints DCGI
In Gujarat, the trial was conducted at 19 posts set up in Gandhinagar and Rajkot districts. In Punjab, Ludhiana and Shaheed Bhagat Singh Nagar were selected for the trial. Nalbari and Sonitpur were the two districts of Assam where the drill had already taken place. The Krishna district of Andhra Pradesh was chosen for the two-day drill. Everywhere the drill went off successfully.
The plan to extend the trial to all states and UT comes amid India’s drug regulatory body, signaling that India could start the new year with a Covid-19 vaccine.
“We will have a Happy New Year with something in hand, that’s all I can hint at,” VG Somani, Comptroller General of Drugs of India (DCGI) said Thursday.
The subject matter expert committee (SEC) of the Central Drug Control Organization (CDSCO) will meet on January 1 to consider the application for emergency use authorization from three companies: Pfizer, Serum Institute of India, which will manufacture the Oxford AstraZeneca vaccine, and Covaxin from Bharat Biotech.
.
